View
33
Download
0
Category
Preview:
DESCRIPTION
Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival in patients with metastatic CRPCa who have progressed after docetaxel-based chemotherapy: Results of COU-AA-301, a randomized placebo controlled phase III study. Authors: de Bono et al, ESMO, October 2010 - PowerPoint PPT Presentation
Citation preview
www.OncologyEducation.ca
Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival in patients with metastatic CRPCa who have progressed after docetaxel-based chemotherapy: Results of
COU-AA-301, a randomized placebo controlled phase III study.
Authors: de Bono et al, ESMO, October 2010Subgroup analysis update: Scher et al, GU ASCO, February 2011Reviewed by: Dr. Lori WoodAbstract: ESMO LBA5, GU ASCO Abstract 4Date posted: May 13, 2011
www.OncologyEducation.ca
Thank you for downloading this update. Please feel free to use it for educational purposes.
Please acknowledge OncologyEducation.ca and Dr. Wood when using these slides.
www.OncologyEducation.ca
BACKGROUND
• After patients with metastatic CRPCa fail docetaxel-based chemotherapy, there were no randomized trials showing a clinically significant benefit to any other agents. In Canada, we often treated patients with mitoxantrone based on phase II data.
• Studies show that CRPCa remains driven by ligand-dependent androgen receptor signaling.
• Abiraterone acetate (AA) is a potent selective inhibitor of CYP17 which is a key enzyme in androgen synthesis.
• Basic science and some clinical data suggest that some CRPCa’s remain dependent on androgen receptor signaling.
www.OncologyEducation.ca
Abiraterone Acetate (AA) 1000 mg po qd +Prednisone 5 mg bidn=797
Placebo +Prednisone 5 mg bidn=398
Metastatic CRPCa
n=1195
Had to HaveReceived Prior Docetaxel Mitoxantrone
1 Outcome = OS
2 Outcomes = PSA Progression,Radiographic Progression, PSA, RR
STUDY DESIGN
www.OncologyEducation.ca
PATIENT CHARACTERISTICS
AA Placebo
Age, Median 69 69
ECOG PS 2 10.7% 11.1%
Significant Pain 44.3% 44.0%
2 Prior Chemotherapy 28.2% 28.4%
Bone Metastases 89.2% 90.4%
Visceral Metastases 29.0% 24.0%
PSA, Median 128.8 137.7
www.OncologyEducation.ca
RESULTS
AA Placebo HR P-value
OS, Median 14.8m 10.9m0.65
(0.54 - 0.77)<0.0001
PSA RR 38% 10% - <0.0001
Radiographic PFS 5.6m 3.6m 0.67 <0.0001
www.OncologyEducation.ca
TOXICITY
AA Placebo
Fluid Retention 30.5% 22.3%
Hypokalemia 17.1% 8.4%
Hypokalemia, grade 3/4 3.8% 0.8%
HTN, grade 3/4 1.3% 0.3%
LFT, abnormal 10.4% 8%
Cardiac 12.5% 9.4%
www.OncologyEducation.ca
SUBGROUP ANALYSIS(GU ASCO 2011)
• All subgroups benefited– ECOG: 0-1 vs. 2– BPI: 4 vs. 4– Prior chemotherapy: 1 vs. 2– Progression: PSA only vs. radiological
PSA– LDH: low vs. high
www.OncologyEducation.ca
STUDY COMMENTARY
• Data reviewed at a pre-specified interim analysis and IDMC recommended study be unblinded.
• AA shows a 3.8m survival advantage over placebo post docetaxel-based chemotherapy in patients with metastatic CRPCa.
• Very well-tolerated.
www.OncologyEducation.ca
BOTTOM-LINE FOR CANADIAN MEDICAL ONCOLOGISTS
• This study will change practice.• Results from another post docetaxel phase III
trial (TROPIC: Cabazitaxel vs. Mitoxantrone) were reported at ASCO 2010. Median OS 15.1m vs. 12.7m
• Given the ease of administration and low toxicity, AA will likely become the standard of care post docetaxel-based chemotherapy in men with metastatic CRPCa.
Recommended